Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Child psychosis study aims to match kids to the right drug

NCT ID NCT04370730

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is following 200 children and teens (ages 7-20) who have experienced psychosis to see if they fall into distinct subgroups. Researchers will use interviews, brain scans, and genetic tests to classify participants. The goal is to see if these subgroups predict how well a child responds to specific antipsychotic medications, potentially leading to more personalized treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which antipsychotic drug works best for a child based on their specific psychosis subtype, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and the findings might not apply to all children with psychosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2021

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 20 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for the Patient: 1. Children and young adults ages 7-20 years with age of onset of psychotic disorder between 7-17 years. 2. Hospitalized or seen for out-patient treatment for a psychotic episode, acute or chronic. 3. DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features. 4. Written informed consent signed by the parents or the individual(s) with legal parental authority, and by the minor patient if his/her condition permits. 5. Written informed consent signed by the patient if he/she is a major, after clinical stabilization (not delusional). 6. Has health insurance coverage from Social Security (France) (not AME coverage). Inclusion Criteria for parents or siblings wishing to participate in the genetic part of the study : 1. Parents : no specific criteria. 2. Siblings : siblings are eligible to participate if there are at least two first-degree relatives with psychotic disorders (including the patient) in the family. 3. Written informed consent for the genetic part of the study signed by any participating parents and siblings. 4. Has health insurance coverage from Social Security (France) (not AME coverage). Exclusion Criteria: 1. Moderate or severe intellectual deficiency (IQ \< 50). 2. Psychoses judged to be secondary to medical illness, medication effects or drugs of abuse. 3. Diagnosis of bipolar disorder. 4. Patients who are under legal guardianship. 5. For the neuroimaging part of the study only : any contraindications to Magnetic Resonance Imaging.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychotic disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disease Progression psychotic disorder Psychotic Disorders schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psychotic disorders Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU de Lille

    NOT_YET_RECRUITING

    Lille, 59037, France

  • CHU de Nice

    NOT_YET_RECRUITING

    Nice, 62000, France

  • CHU de Rouen

    NOT_YET_RECRUITING

    Rouen, 76031, France

  • CHU de Rouvray

    NOT_YET_RECRUITING

    Rouen, 76031, France

  • Fondation Vallée, Gentilly

    NOT_YET_RECRUITING

    Gentilly, 94257, France

  • Pitié Salpétrière

    RECRUITING

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.